Agreement Signed Between Pending AI and Thieme Group to Take Drug Discovery Research to the Next Level
Stuttgart, 22 May, 2026 – Thieme Group and Pending AI have formed a commercial and data licensing partnership. With access to the Science of Synthesis (SOS) Datasets, Pending AI can leverage its state-of-the-art artificial intelligence infrastructure to unlock unprecedented possibilities in small molecule discovery for pharmaceutical development.
Pending AI and Thieme Group have signed a global cooperation agreement to provide the scientific community with next-generation AI infrastructure. With access to Thieme’s highly curated, gold-standard SOS Datasets, Pending AI can leverage its state-of-the-art artificial intelligence platform to unlock new possibilities in small molecule discovery.
“We have been collaborating with Pending AI on the SOS dataset for a few years, with a focus on improving their retrosynthesis algorithms. We are very happy that our efforts have resulted in a cooperation agreement,” said Dr. Sascha Hausberg, Senior Director eProducts at Thieme Group.
Dr. David Almeida Cardoso, Pending AI’s Vice President, Business Development and Strategy, added: “We are pleased to collaborate with Thieme. The quality and depth of the SOS Datasets provide a strong foundation for advancing our next-generation AI-driven retrosynthesis capabilities and supporting more-efficient small molecule research worldwide.”
About Thieme’s SOS Datasets
The high-quality SOS Datasets are an essential knowledge base for chemists working in “real life” as well as for “virtual chemists”. They are relevant to researchers working in designing organic syntheses or in computational investigations of chemical reactivity as well as to data scientists.
About Pending AI
Pending AI has developed a world-first pharmaceutical discovery platform covering target selection through to hit identification and lead optimization, leveraging scalable artificial intelligence and quantum mechanics to usher in a new paradigm of medicinal innovation. With a global presence, Pending AI are committed to leveraging its unique capabilities for first-in-class drug discovery activities against biologically validated cancer targets, as well as providing discovery software tools to academic, government and pharmaceutical stakeholders.
Contact Us to Access Pending AI’s New-Gen Capabilities – Powered by SOS!
If you are interested in learning how Pending AI’s next-generation AI-driven synthesis prediction solution, TwinOracle, which completely rethinks how synthesis prediction is undertaken and is powered by SOS Datasets, can support your small molecule research, please contact the team via the ‘Contact Us’ button on the Pending AI website.
Need More Information? Reach Out to Us!
If you are interested in learning how Thieme’s Science of Synthesis Platform can enable your research, please contact us.
Our SOS team is happy to help.
